Rodríguez-Silva VY, Vega-Mendoza S

Language: Spanish
References: 17
Page: 103-108
PDF size: 131.53 Kb.

ABSTRACT

Objective: To evaluate the characteristics and prevalence of patients with type 2 Diabetes Mellitus (DM2) under prescription of oral hypoglycemic agents who meet insulinization criteria. Methods: descriptive crosssectional study. 367 records of patients with DM2, aged 30 to 70 years attending the Family Medicine Unit No. 20 in Mexico City, were analyzed, with at least three months of treatment with oral hypoglycemic agents. Sociodemographic and clinical characteristics of DM2, type of oral hypoglycemic agent, comorbidities and the criteria for initiation of insulin treatment were recorded according to the American Diabetes Association and the European Association for the Study of Diabetes. Results: of the total number of patients, the average age was 56.5 years (SD±9.0), 58.3% were women, and 50.1% were controlled (n=184). 37.6% of patients met the criteria for insulinization, their characteristics were: age 61-70 years, 42.8%; women, 52.9%; dedicated to the household, 32.6%; married, 66.7%; DM2 time of evolution of 1-5 years, 32.6%; 95.7% presented comorbidities, obesity, 52.9%; arterial hypertension, 52.2%; and dyslipidemia, 51.4%; neuropathy, 18.8%, nephropathy, 3.6%, and retinopathy, 2.9%. Conclusions: there was a high percentage of uncontrolled patients under prescription of oral hypoglycemic agents, more than one third met the criteria for initiation of insulin therapy, while most of these patients had some type of comorbidity.

REFERENCES

1. Brison DW. Definition, diagnosis, and classification of Diabetes Mellitus and its Complications. World Health Organization. Department of Noncommunicable Disease Surveillance [Internet]. [Citado 2020 Nov 09]. Disponible en: https:// apps.who.int/iris/handle/10665/66040

2. Organizacion Mundial de la Salud. Informe Mundial Sobre la diabetes [Internet]. [Citado 2021 Ago 01]. Disponible en: www.who.int

3. Romero MM. Diseño metodológico de la encuesta nacional de salud y nutrición de medio camino 2016. Salud Publica Mex. 2017;59(3):299-305.

4. Alcocer J. Sistema de Vigilancia Epidemiológica de Diabetes Tipo 2 [Internet]. [Citado 2021 Ago 01]. Disponible en: https://epidemiologia.salud. gob.mx/gobmx/salud/documentos/manuales/10_ Manual_DT2.pdf

5. Fuente GV. Insulinización en la diabetes mellitus tipo 2 alternativas de intensificación. Med Buenos Aires. 2016;76(2):173-179.

6. Gómez HR. Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Rev Clin Esp. 2018;(2):74-88.

7. De la Fuente JS, Granja BV, Ferrari PJM, Valero ZMA, López-Coterilla HA. Tipos de insulinoterapia. Rev Clin Esp. 2008;(2):76-86.

8. Levin PA. Health outcomes associated with initiation of basal insulin after 1, 2, or ≥ 3 oral antidiabetes Drug(s) among managed care patients with type 2 diabetes. J Manag Care Pharm. 2015;21(12):1172-1182.

9. Care D, Suppl SS. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(January):66-76.

10. Wu H, Liu J, Lou Q, Liu J, Shen L, Zhang M, Lv X, Gu M, Guo X. Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. Medicine (Baltimore). 2017;96(35):e7533.

11. Ovalle-Luna OD, Jiménez-Martínez IA, Rascón- Pacheco RA, Gómez-Díaz RA, Valdez-González AL, Gamiochipi-Cano M, et al. Prevalencia de complicaciones de la diabetes y comorbilidades asociadas en medicina familiar del Instituto Mexicano del Seguro Social. Gac Med Mex. 2019;155(1):30- 38.

12. Moradi Y, Baradaran HR, Djalalinia S, Chinekesh A, Khamseh ME, Dastoorpoor M, Sioofy-Khojine AB, Saed L, Qorbani M. Complications of type 2 diabetes in Iranian population: An updated systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(3):2300-2312.

13. Abu-Ashour W, Chibrikova L, Midodzi WK, Twells LK, Gamble JM. Factors associated with early insulin initiation in Type 2 diabetes: a Canadian cross-sectional study. Diabet Med. 2017;34(2):229-234.

14. Rodolfo LC. Clinical inertia in insulin prescription for patients with type 2 diabetes mellitus at a primary health care institution of Cartagena, Colombia. Rev Fac Med. 2018;66 (4):551-5.

15. Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care. 2013;36 Suppl 2(Suppl 2):S190-7.

16. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.

17. Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes. 2017;8(4):120-129.